Krebs Biochemicals & Industries Ltd (KREBSBIO) is currently trading at 54.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Krebs Biochemicals & Industries Limited manufactures Active Pharmaceutical Ingredients (APIs) and drug intermediates using fermentation, enzymatic and chemical synthesis routes, and provides contract manufacturing to large pharmaceutical and multinational customers; the company grew capacity from 60 TPA to 150 TPA and historically operated plants at Vizag and Nellore. The quarter and half‑year to 30 September 2025 showed a sharp revenue contraction: Q2 revenue from operations was Rs. 548.09 lakhs versus Rs. 1,285.52 lakhs a year earlier, and H1 revenue was Rs. 964.83 lakhs versus Rs. 2,574.42 lakhs, reflecting a material disruption to manufacturing and sales. Krebs reported a sizeable operating loss — PBT of Rs. (614.28) lakhs for the quarter — while balance sheet leverage remains elevated with consolidated borrowings exceeding Rs. 21,220 lakhs and negative total equity of roughly Rs. (14,624) lakhs as of 30 September 2025. A key operational constraint is the continued closure of the Vizag manufacturing unit following an Andhra Pradesh Pollution Control Board order in February 2025, which materially reduced production and revenue visibility; the company states the unit remained closed as at the reporting date. Despite material headwinds, the statutory auditor issued an unmodified review report on the unaudited results, and the company retains tangible plant and equipment (PPE around Rs. 14,523 lakhs) and historical technical capability in fermentation that could support a restart or strategic transaction.

Over the past 52 weeks, Krebs Biochemicals & Industries Ltd has traded between a low of ₹38.52 and a high of ₹76.72. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Krebs Biochemicals & Industries Ltd has a market capitalization of approximately 114.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Krebs Biochemicals & Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -8.11 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 114.25 Cr, Krebs Biochemicals & Industries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Krebs Biochemicals & Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Krebs Biochemicals & Industries Ltd is -8.11. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.